Definitive Contract 75A50124C00061
Award Date
9/30/24
Potential Completion Date
9/30/28
Potential Value
$14M
Awardee
Partner Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Lexington, MA 02421, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
100
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $83,515,143.92 firm fixed-price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Partner Therapeutics, Inc., a for-profit biopharmaceutical company in Lexington, Massachusetts. The contract is for the supply of LEUKINE 250MCG VIL INJ (5PKG), a critical medical countermeasure. This delivery order is part of Partner Therapeutics' broader contract...
This federal contract award, valued at $2,807.43, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LEUKINE 250 MCG VIALS, a medical product, and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...
This is a federal contract award to Spero Therapeutics, Inc. valued at $49,795,199.00 for the development of SPR994, an oral carbapenem antibiotic to treat drug-resistant Gram-negative bacterial infections. The contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is a definitive, cost-sharing agreement with an ultimate completion date of October 31, 2026....
<p>This is a $199,833 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Cleveland Leukemia Therapeutics LLC, a small business contractor, for the development of a targeted therapy for acute myeloid leukemia. The contract has a completion date of September 29, 2012 and was awarded on September 30, 2011. This award appears to be part of the agency's TAS 75 0849 program focused on Topic 255 for the development of targeted therapies.</p>
This federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Amgen USA Inc. The $1,052,008,540.28 definitive, firm-fixed price contract is for the delivery of an FDA-approved thrombopoietin receptor agonist drug to be used in the Strategic National Stockpile to treat thrombocytopenia (low platelet count) resulting from acute radiation syndrome in the event of...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $5,275,114 definitive, cost-plus-fixed-fee contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Keranetics Inc., a for-profit medical research and development company. The contract is for preclinical, regulatory, and manufacturing development activities, with a completion date of May 30, 2026. The contract is not set aside. Keranetics has previously supported HHS and Department of Defense medical...
This is a delivery order (HT942525F0013) awarded to Leinco Technologies, Inc., a self-certified small disadvantaged business and manufacturer of goods, by the Defense Health Agency (DHA) on October 31, 2024. The $33,125.00 firm fixed-price contract is for the provision of monoclonal antibodies derived from in-vivo genetically immunized knockout mice expressing the interferon-alpha/beta receptor alpha chain protein. This contract supports the agency's research and development efforts related to...
This is a $413,697.84 Cost Plus Fixed Fee delivery order awarded by the U.S. Army Medical Command (MEDCOM) to Leidos, Inc. The contract is under the Medical Product Research and Development indefinite delivery vehicle (IDV) and is for a Repeat Dose Toxicity Study. Leidos has subcontracted a portion of the work to SNBL U.S.A., LTD. The contract does not have a set-aside designation. This award supports MEDCOM's medical research programs, which encompass efforts related to traumatic brain...